PeptideDB

CJC-1295 vs Ipamorelin

Not really rivals — a GHRH analog and a GHRP studied as a synergistic pair.

In short: CJC-1295 and Ipamorelin act on different receptors and are most often researched in combination rather than as alternatives.

Side-by-side comparison

CJC-1295Ipamorelin
Class / subtitleLong-acting GHRH analogSelective ghrelin-mimetic GHRP
Research statusIn clinical trialsIn clinical trials
CategoriesGrowth HormoneGrowth Hormone
Primary targetsGHRH receptorGHS-R1a (ghrelin receptor)
Half-life≈6–8 days with DAC; ≈30 minutes without DAC (Mod GRF 1-29)≈2 hours
SequenceModified GRF(1-29) tetrasubstituted analog with a Drug Affinity Complex (DAC) linkerAib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular formulaC152H252N44O42C38H49N9O5
Molecular weight≈3647.2 g/mol (with DAC)711.85 g/mol
CAS number863288-34-0170851-70-4
Routes (research)subcutaneoussubcutaneous
CJC-1295In clinical trials

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) engineered for a dramatically extended half-life, studied for its ability to raise growth hormone and IGF-1 levels.

Full CJC-1295 profile
IpamorelinIn clinical trials

Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates GH release with minimal effect on cortisol, prolactin, or appetite, making it the cleanest of the classic GHRPs.

Full Ipamorelin profile

FAQ

What is the main difference between CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin act on different receptors and are most often researched in combination rather than as alternatives.

What is the half-life of CJC-1295 compared to Ipamorelin?

CJC-1295: ≈6–8 days with DAC; ≈30 minutes without DAC (Mod GRF 1-29). Ipamorelin: ≈2 hours.

Provided for research and educational reference only — see ourdisclaimer.